QNRX — Quoin Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $0.10m
- -$11.03m
- 23
- 60
- 15
- 24
Annual cashflow statement for Quoin Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | 20-F | 10-K | 10-K | 10-K |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | fx Final | Final | Final | Final | Final |
| Net Income/Starting Line | -5.26 | -21.5 | -9.38 | -8.69 | -8.96 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.646 | 14.3 | 0.177 | 0.623 | 1.01 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.102 | 1.33 | 0.62 | 0.095 | -0.002 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -4.5 | -5.72 | -8.48 | -7.86 | -7.86 |
| Capital Expenditures | -0.096 | -0.625 | -0.25 | — | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.012 | — | -9.9 | 2.19 | -1.89 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.084 | -0.625 | -10.1 | 2.19 | -1.89 |
| Financing Cash Flow Items | — | 10.2 | 14.9 | -0.033 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.89 | 13.5 | 14 | 5.22 | 11 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.332 | 7.16 | -4.62 | -0.459 | 1.22 |